Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Tissue Regenix Group

17 Dec 2025 18:00

RNS Number : 9811L
FTSE Russell
17 December 2025
 

 

 

Suspended Company Notice - Deletion

17 December 2025

Further to the notice released on 19 November 2025, the following company has been suspended 40 business days without indication of resumption. In accordance with the Suspension of Dealing rule, it will be removed from the FTSE Russell Index for the open of 22 December 2025 at nominal value (0.0001).

 

· Tissue Regenix Group (BNTXR10, FTSE AIM All-Share Index)

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+61 (0) 2 7228 5659

Hong Kong

+852 2164 3333

Japan

+81 3 6441 1430

London

+44 (0) 20 7866 1810

New York

+1877 503 6437

Alternatively, please visit our website at lseg.com/ftse-russell

Terms of Use | Copyright © 2025 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FTSPKOBBBBDDFBD
Date   Source Headline
30th Mar 20207:00 amRNSUpdate in relation to working capital position
20th Mar 20207:00 amRNSDirectorate Change
6th Feb 20207:15 amEQSHardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand
4th Feb 202011:47 amRNSResolution of Cyber Security Incident
28th Jan 202010:02 amRNSNotice of cyber security incident
22nd Jan 20207:00 amRNSTrading Update
14th Jan 20204:40 pmRNSSecond Price Monitoring Extn
14th Jan 20204:35 pmRNSPrice Monitoring Extension
21st Nov 20194:35 pmRNSPrice Monitoring Extension
18th Nov 20194:03 pmRNSDirectorate Change
14th Nov 20194:00 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSUpdated loan facility agreement with MidCap
13th Nov 20193:35 pmRNSHolding(s) in Company
13th Nov 20193:17 pmRNSHolding(s) in Company
11th Nov 20192:05 pmRNSSecond Price Monitoring Extn
11th Nov 20192:00 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSUpdate in relation to loan facility
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.